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Abstract
Hypoxia-inducible factor-1 (HIF-1) plays a key role in cell adaptation to low oxygen and stabilization of HIF-1 is vital to
ensure cell survival under hypoxia. Diabetes has been associated with impairment of the cell response to hypoxia and
downregulation of HIF-1 is most likely the event that transduces hyperglycemia into increased cell death in diabetes-
associated hypoxia. In this study, we aimed at identifying the molecular mechanism implicated in destabilization of HIF-1 by
high glucose. In this work, we identified a new molecular mechanism whereby methylglyoxal (MGO), which accumulates in
high-glucose conditions, led to a rapid proteasome-dependent degradation of HIF-1a under hypoxia. Significantly, MGO-
induced degradation of HIF-1a did not require the recruitment of the ubiquitin ligase pVHL nor did it require hydroxylation
of the proline residues P402/P564 of HIF-1a. Moreover, we identified CHIP (Carboxy terminus of Hsp70-Interacting Protein)
as the E3 ligase that ubiquitinated HIF-1a in the presence of MGO. Consistently, silencing of endogenous CHIP and
overexpression of glyoxalase I both stabilized HIF-1a under hypoxia in the presence of MGO. Data shows that increased
association of Hsp40/70 with HIF-1a led to recruitment of CHIP, which promoted polyubiquitination and degradation of HIF-
1a. Moreover, MGO-induced destabilization of HIF-1a led to a dramatic decrease in HIF-1 transcriptional activity. Altogether,
data is consistent with a new pathway for degradation of HIF-1a in response to intracellular accumulation of MGO.
Moreover, we suggest that accumulation of MGO is likely to be the link between high glucose and the loss of cell response
to hypoxia in diabetes.
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Introduction
Cell response to ischemia is primarily regulated by the
transcription factor HIF-1 (hypoxia-inducible factor-1) [1] that
triggers protective and adaptive mechanisms, promoting cell
survival under hypoxia. Thus, any mechanism that destabilizes
HIF-1 has a negative impact on cell adaptation to hypoxia. HIF-1
is a heterodimer composed of two subunits: a labile HIF-1a
subunit and a stable HIF-1b subunit. Under normoxia, HIF-1a is
hydroxylated on prolines 402 and 564 in the oxygen dependent
degradation domain (ODD) by specific prolyl hydroxylases. Once
hydroxylated, HIF-1a binds to the von Hippel Lindau protein
(pVHL), which is part of an E3 ligase complex, resulting in HIF-1a
polyubiquitination and subsequent proteasomal degradation
[2,3,4]. In addition, asparagine 803 is also hydroxylated inhibiting
the interaction of HIF-1a with the co-activator p300, leading to
further repression of HIF-1 transcriptional activity [5]. When
oxygen becomes limiting, the proline residues are not hydroxyl-
ated and HIF-1a escapes degradation, accumulating in the cell.
HIF-1a is imported into the nucleus, dimerizes with HIF-1b and
binds to hypoxia responsive elements (HREs), enabling transcrip-
tional activation of more than 70 genes that help cells to cope and
survive under hypoxia [1,6], such as the vascular endothelial
growth factor (VEGF).
Recently, it was shown that diabetes and hyperglycemia leads to
downregulation of HIF-1 [7,8,9]. For example, downregulation of
HIF-1 in response to hyperglycemia is likely to account for the
decreased arteriogenic response triggered by myocardial ischemia
in diabetic patients [10,11]. Moreover, blood glucose levels were
shown to vary in linear relation with fatal outcome after an acute
hypoxic challenge, suggesting a deleterious influence of hypergly-
cemia on the ability of tissues to adapt to low oxygen [12]. In
addition, levels of HIF-1 were found to be downregulated in
biopsies from ulcers of diabetic patients as compared to venous
ulcers that share the same hypoxic environment but are not
exposed to hyperglycemia [7]. These and other evidences strongly
suggest that cell and tissue dysfunction associated with diabetes is
related, at least in part, with loss of cell response to hypoxia.
However, the molecular mechanisms underlying this dysfunction
remain to be elucidated.
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oxal (MGO) is the link between high glucose and destabilization of
HIF-1 in diabetes. Methylglyoxal (MGO) is a highly reactive a-
oxoaldehyde formed as a by-product of glycolysis [13,14]. Indeed,
high glucose leads to intracellular accumulation of MGO in
several tissues and increased concentration of MGO in cells and
tissues has been implicated in the pathophysiology of a variety of
diseases, including many diabetic complications [13,14]. MGO is
known to react with the free amino groups of lysine and arginine
residues, leading to the formation of advanced glycation end
products (AGEs) [13], and increased levels of MGO have
deleterious effects in a number of essential signaling pathways
[15,16]. Of significance, AGEs were shown to impair the
angiogenic process in a model of ischemia-induced retinopathy
[17].
Data presented in this paper shows that MGO was able to
induce the degradation of HIF-1a and to decrease the transcrip-
tional activity of HIF-1. The MGO-induced destabilization of
HIF-1a did not involve recruitment of the pVHL ubiquitin ligase
nor did it require hydroxylation of the prolines residues P402/
P564 of HIF-1a. We identified CHIP (Carboxyl terminus of the
Hsc70-Interacting Protein) as the ubiquitin ligase that targets HIF-
1a for degradation in the presence of MGO, by a mechanism that
requires prior recruitment of the molecular chaperones Hsp40 and
Hsp70.
Results
Intracellular accumulation of MGO decreased the half-life
of HIF-1a
Hyperglycemia was shown to be involved in the loss of cell
response to hypoxia in diabetes, through a mechanism that is likely
to involve downregulation of HIF-1a. Indeed, data shows that
levels of HIF-1a were downregulated under hypoxia in cells
treated with high glucose over a period of 10 days, as compared to
cells maintained in basal glucose concentration (Figure 1A). In this
study, we used a retinal pigment epithelial cell line (ARPE-19) to
investigate the role of high glucose in regulation of HIF-1. Retinal
pigment epithelial (RPE) cells are a good model to evaluate cell
response to hypoxia since these cells are extremely sensitive to
variations in oxygen [18] and glucose concentrations [19] and are
a major source of VEGF in the retina, a gene well known to be
upregulated by hypoxia [6,20].
To further emphasize the relevance of high glucose in
downregulation of HIF-1a, we assessed the intracellular levels of
MGO following exposure of ARPE-19 cells to high glucose. Data
shows that after 10 days of incubation with high glucose (40 mM),
the intracellular levels of MGO increased by about 23%, reaching
the concentration of 0.4560.024 mM (Figure 1B). Consistently,
Figures 1C and 1D show that treatment of cells with MGO
induced destabilization of HIF-1a, which was previously accumu-
lated under hypoxia, in a dose and time-dependent manner. After
30 minutes of incubation with 3 mM MGO there was a decrease
of about 50% in the levels of HIF-1a, whereas after 3 hours of
incubation HIF-1a was virtually undetectable (Figure 1D). As a
control, we show that the effect of MGO cannot be generalized to
all transcription factors. Indeed, MGO did not downregulate other
transcription factors, such as NF-E2 related factor 2 (Nrf-2)
(Figure 1E). Moreover, incubation of RPE cells with 3 mM MGO
for 30 minutes or for 3 hours resulted in an intracellular
accumulation of MGO of 1.5460.246 mM or 0.9660.247 mM,
respectively (Figure 1F). The decrease of MGO after 3 hours of
incubation probably reflects scavenging by glyoxalases [21,22], as
well as irreversible binding of MGO to proteins and other cell
components [14]. The range of MGO concentrations used in this
work have been widely used in other studies [15,23] and result in
intracellular concentrations of MGO that are within the
physiological range reported in pathological conditions, such as
diabetes [24,25,26,27].
Additionally, pulse-chase experiments clearly showed that
MGO decreased the half-life of HIF-1a by about two fold, from
98 minutes to 47 minutes (Figure 1G). This indicates that MGO
did indeed downregulate HIF-1a by promoting an increased
degradation of the protein.
Significantly, overexpression of glyoxalase I (GLO I), the rate-
limiting enzyme involved in the detoxification of MGO, prevented
intracellular accumulation of MGO (Figure 2A) and promoted
stabilization of HIF-1a under hypoxia following treatment with
either high glucose (Figure 2B) or MGO (Figure 2C). Although we
cannot exclude that other putative AGE precursors are also
involved in HIF-1a destabilization under high glucose, these data
clearly support a role for MGO in destabilization of HIF-1a under
high glucose. Indeed, overexpression of GLO I stabilized HIF-1a
(Figure 2B), which indicates that an increase of about 23% in the
intracellular levels of MGO (Figure 1B) appears to be sufficient to
promote a strong decrease on the levels of HIF-1a.
MGO induced a decrease of the HIF-1 transcriptional
activity
The downregulation of HIF-1a protein levels following
exposure to MGO consistently led to a decrease in HIF-1
transcriptional activity. To initiate transcription, HIF-1 binds to
the HREs of a number of target genes, including VEGF. Data
represented in Figure 3A shows that hypoxia led to a significant
increase in HIF-1 transcriptional activity as evaluated by an HRE-
luciferase associated reporter gene assay. Incubation with MGO
dramatically decreased the activity of luciferase, suggesting a
strong decrease in HIF-1 transcriptional activity. Consistent with
this decrease in the transcriptional activity, the levels of VEGF
mRNA also decreased in the presence of MGO as compared to
hypoxic cells cultured in the absence of MGO (Figure 3B). The
levels of VEGF secreted into the culture medium also decreased as
compared to cells subjected only to hypoxia (Figure 3C). We
believe that the observed decrease on the transcriptional activity of
HIF-1 is, most likely, due to changes on the total amount of the
HIF-1a protein, rather than effective decreased activity of HIF-1
to transactivate its target genes and activate the transcriptional
machinery. However, this effect may not be excluded.
The downregulation of HIF-1 transcriptional activity under
normoxia following treatment with MGO can be ascribed to low,
but detectable, HIF-1a levels in controls, which further decreased
after treatment with MGO (as revealed by longer exposures of
immunoblot membranes).
MGO induced polyubiquitination and proteasome-
dependent degradation of HIF-1a
MGO has recently been shown to modify HIF-1a on arginine
residues [22], probably leading to changes in protein conformation.
Indeed, immunoprecipitation experiments showed that MGO
modified lysine and arginine residues of HIF-1a, increasing its
immunoreactivity against Ne-carboxymethyl-lysine (CML) and Na-
acetyl-Nd(5-hydro-5-methyl)-4-imidazolone (MG-H1) antibodies,
respectively (Figure 4A). Thus, we hypothesized that modification
by MGO might stimulate proteasome-dependent degradation of
HIF-1a, as a result of post-translational modifications.
Treatment of cells with proteasome inhibitors, following
incubation with MGO, resulted in the accumulation of high
MGO Induces HIF-1a Ubiquitination by CHIP
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antibodies (Figure 4B). It is interesting to note that the pattern of
HIF-1a ubiquitination in the presence of MGO varied in a time-
dependent manner. Indeed, for the initial time points a
characteristic high-molecular weight ladder can be observed
(Figure 4B). However, this ladder disappeared for longer
incubations, which was accompanied by the accumulation of
higher molecular weight forms of HIF-1a on the top of the gel
(Figure 4C). These observations were likely to result from a
gradual and time-dependent ubiquitination of the protein in
response to MGO treatment, resulting in the accumulation of
increasingly higher molecular weight forms of the protein. It
should also be noted that the effect of MGO under hypoxia is
quite different from the effect observed under proteasome
inhibition (compare lane 2 with lane 4 on Figure 4C). Indeed,
under hypoxia and MGO, HIF-1a was readily degraded, whereas
in the presence of MG132 there was an apparent loss of HIF-1a
(120 kDa), with an accumulation of high molecular weight forms
of the protein that corresponded to ubiquitinated forms of HIF-1a,
as confirmed by immunoprecipitation experiments (Figure 4D). It
Figure 1. High glucose induced intracellular accumulation of methylglyoxal, which in turn led to decreased levels of HIF-1a. (A)
ARPE-19 cells were grown in 15 mM (basal DMEM: F12 medium) or 40 mM of D-glucose during 10 days. During the last 61 hours of incubation, cells
were exposed to hypoxia (2% O2). After the treatments, the proteins were separated by SDS-PAGE, transferred to PVDF membranes and probed
against HIF-1a and actin. The results represent the mean 6 SD of at least three independent experiments. * p,0.05, significantly different from
control (t test). (B) ARPE-19 cells were grown in DMEM: F12 medium containing 15 mM or 40 mM of D-glucose during 10 days. Cells were then lysed
in acetic acid (0.1 M) and the intracellular levels of MGO were determined by HPLC analysis after derivatization with DDB. The results represent the
mean 6 SD of at least three independent experiments. * p,0.05, significantly different from control (t test). (C and D) ARPE-19 cells were exposed to
hypoxia (2% O2) for 6 hours and MGO (1 mM or 3 mM) was added for 30 minutes or 3 hours. The cell lysates were analyzed by immunoblot using
antibodies for HIF-1a and actin. (E) ARPE-19 cells were treated with different MGO concentrations (100 mM to 3 mM) for 2 hours. The cell lysates were
analyzed by western blot using antibodies for Nrf-2 and actin. (F) ARPE-19 cells were treated with 3 mM of MGO for 30 minutes or 3 hours. Cells were
then lysed in acetic acid (0.1 M) and the intracellular levels of MGO were determined by HPLC after derivatization with DDB. The results represent the
mean 6 SD of at least three independent experiments. * p,0.05 and ** p,0.01, significantly different from control (one-way ANOVA with the
Dunnet’s comparison test). (G) After metabolic labeling with L-[
35S] methionine/cysteine under hypoxia, ARPE-19 cells were maintained under
hypoxia, either in the absence or the presence of MGO (3 mM). Cells were harvested at 0, 10, 30, 60 and 90 minutes in 0.5% NP-40 lysis buffer. HIF-1a
was immunoprecipitated and radiolabeled HIF-1a protein was assessed by SDS-PAGE and autoradiography.
doi:10.1371/journal.pone.0015062.g001
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low percentage of a non-ionic detergent (0.5% NP-40) with low
solubility potential in contrast to the 2x Laemmli buffer used to
prepare whole cell lysates such as the data presented in Figures 4B
and 4C. This may explain the poor detection of high molecular
weight bands, in the presence of MGO, in the panel correspond-
ing to the input samples of the IP experiments.
Previous results suggested that MGO-induced degradation of
HIF-1a is proteasome-dependent and involves ubiquitination of
the protein. Immunofluorescence data further confirmed these
results. Data shows that proteasome inhibition per se decreased the
levels of polyubiquitin conjugates in the nucleus, consistent with
previous reports [28,29]. However, addition of MGO changed the
distribution of ubiquitin in the cell, strongly increasing the nuclear
co-localization between ubiquitin conjugates and HIF-1a
(Figure 4E). We further show that the proteasome inhibitor
MG132 (or epoxomicin) prevented MGO-induced degradation of
HIF-1a and extended the half-life of the protein by about 1.7 fold
(Figure 4F). Taken together, these observations indicate that HIF-
1a was modified by MGO and that such modification resulted in
ubiquitin-dependent degradation of the protein. However, because
proteasome inhibitors did not fully prevent HIF-1a degradation, it
seems reasonable to suggest that other degradation pathways are
likely to be involved in HIF-1a degradation induced by MGO. An
alternative explanation is that, even in the presence of inhibitors
such as MG132, a residual proteasomal activity was maintained
(Figure 4G), which might be sufficient to sustain some level of
degradation of HIF-1a in the presence of MGO.
Figure 2. Glyoxalase I overexpression significantly stabilized HIF-1a under high glucose or methylglyoxal treatment. (A) ARPE-19 cells
were infected with pAD hGLOI adenovirus for 48 hours. By the end of infection, cells were treated with 3 mM of MGO for 3 hours and were,
subsequently, lysed in acetic acid (0.1 M). The intracellular levels of MGO were determined by HPLC after derivatization with DDB. The results
represent the mean 6 SD of at least three independent experiments. *** p,0.001, significantly different from Mock; ### p,0.001, significantly
different from Mock + MGO3h (one-way ANOVA with Tukey’s multiple comparison test). (B) ARPE-19 cells were grown in 15 mM (basal DMEM: F12
medium) or 40 mM of D-glucose during 10 days. After 8 days of incubation, cells were infected with pAd hGLOI adenovirus for 48 hours. During the
last 6 hours of incubation, cells were subjected to hypoxia and subsequently lysed. Proteins were separated by SDS-PAGE, transferred to PVDF
membranes and analyzed by immunoblot against HIF-1a and actin. (C) ARPE-19 cells were infected with pAD hGLOI adenovirus for 48 hours. During
the last 6 hours of incubation, cells were subjected to hypoxia in the presence of MGO (3 mM for 3 hours). Subsequently, cells were lysed and the
proteins were separated by SDS-PAGE, transferred to PVDF membranes and probed against HIF-1a and actin. The word ‘‘Mock’’ in the figures refers to
a control with an empty vector.
doi:10.1371/journal.pone.0015062.g002
Figure 3. Methylglyoxal decreased the transcriptional activity of HIF-1 and the release of VEGF121/165 into the medium. (A) ARPE-19
cells were transiently transfected with the pT81 HRE-luciferase vector and were subjected to hypoxia (2% O2) for 6 hours in the absence or presence
of MGO (1 mM for 4 hours). Subsequently, the luciferase activity was determined and the values were expressed as fold induction over control. (B)
ARPE-19 cells were subjected to hypoxia (2% O2) for 6 hours either in the absence or the presence of MGO (1 mM for 4 hours). Total RNA was used to
synthesize cDNA, which, in turn, was used as template to quantify VEGF mRNA and 18S rRNA through RT-PCR. (C) ARPE-19 cells were subjected to
hypoxia (2% O2) for 6 hours either in the absence or in the presence of MGO (1 mM for 4 hours). The concentration of the diffusible VEGF121 and
VEGF165 isoforms were determined by ELISA using a monoclonal antibody for human VEGF. The results represent the mean 6 SD of at least three
independent experiments. ** p,0.01 and *** p,0.001, significantly different from control; ## p,0.01 and ### p,0.001, significantly different
from hypoxia condition (one-way ANOVA).
doi:10.1371/journal.pone.0015062.g003
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PLoS ONE | www.plosone.org 4 November 2010 | Volume 5 | Issue 11 | e15062Figure 4. Methylglyoxal modified HIF-1a and induced its polyubiquitination. (A) ARPE-19 cells were subjected to hypoxia (2% O2) for
6 hours and then incubated with MGO (3 mM) for 40 and 70 minutes. HIF-1a was immunoprecipitated and the immunoprecipitates were probed
against CML and MG-H1. (B and C) ARPE-19 cells were treated with MG132 (20 mM) for 4 hours or subjected to hypoxia (2% O2) for 6 hours and then
incubated with MGO (3 mM) for 30 minutes, 90 minutes (B) or 3 hours (C). The cell lysates were analyzed by immunoblot against HIF-1a and the
PVDF membranes were overexposed to reveal higher molecular weight bands; * HIF-1a of 120 kDa; ** posttranslationally modified HIF-1a (with
higher molecular weights). (D) ARPE-19 cells were treated with MG132 (20 mM) for 4 hours either in the presence or absence of MGO (3 mM) for the
last 90 minutes. HIF-1a was immunoprecipitated and immunoprecipitates were probed against HIF-1a and ubiquitin (P4D1). IP controls were carried
out both with no antibody and with an irrelevant mouse IgG1 antibody (anti-GFP). (E) ARPE-19 cells cultured in coverslips were transfected with HA
tagged HIF-1a. Subsequently, cells were treated with MG132 (20 mM) for 4 hours in the absence or presence of MGO (3 mM) for 90 minutes. Cells
were fixed with 4% PFA for 10 minutes and used for immunocytochemistry using specific antibodies directed against HA and ubiquitin (FK1). (F)
ARPE-19 cells were incubated with L-[
35S] methionine/cysteine under hypoxia. After metabolic labeling, cells were maintained under hypoxia, in the
presence of 3 mM of MGO and either in the absence or presence of MG132 (20 mM). Cells were harvested at 0, 10, 40 and 70 minutes in 0.5% NP-40
lysis buffer. HIF-1a was immunoprecipitated and radiolabeled HIF-1a protein was assessed by SDS-PAGE and autoradiography. (G) ARPE-19 cells were
treated with the proteasome inhibitor MG132 (20 mM) for 4 hours, either in the absence or presence of MGO (3 mM for 3 hours). The 20S proteasome
activities were determined by in vitro fluorogenic assays, using specific substrates for each activity: Suc-LLVY-MCA (chymotrypsin-like activity), Z-LLE-
MCA (caspase-like activity) and Boc-LRR-MCA (trypsin-like activity). The values reported in the graph correspond to measurements at 30 minutes of
activity.
doi:10.1371/journal.pone.0015062.g004
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MGO-induced destabilization of HIF-1a
The canonical pathway for HIF-1a degradation requires
recruitment of the ubiquitin ligase pVHL and prior hydroxylation
of prolines 402 and 564 on HIF-1a. ARPE-19 cells were
transfected with a mutant HIF-1a where the proline residues
402 and 564 were mutated to alanine (P402A/P564A). Results
presented in Figure 5A show that mutant HIF-1a was readily
degraded in the presence of MGO indicating that prolines 402 and
564 were not required for MGO-induced degradation of HIF-1a.
Moreover, both WT and mutated HIF-1a accumulated as high
molecular weight bands in the presence of proteasome inhibitors
and MGO, indicating that the mechanism whereby mutant HIF-
1a is degraded in the presence of MGO did not require proline
hydroxylation but was still dependent on the proteasome
(Figure 5B). To further confirm that this new pathway is
independent on pVHL, a VHL deficient cell line (RCC4
VHL
2/2) was treated with MGO. Results in Figure 5C show
that in untreated cells, HIF-1a was inherently stable, whereas
treatment with MGO resulted in the destabilization and rapid
degradation of the transcription factor.
CHIP induced ubiquitination of HIF-1a in the presence of
MGO
MGO was likely to destabilize HIF-1a by inducing post-
translational modification of the transcription factor, thus we
suggestedthat ligasesthat targetpost-translationalmodified proteins
were likely candidates to promote HIF-1a ubiquitination. Because
CHIP is a chaperone-binding ligase that bridges the ubiquitin-
proteasome pathway and molecular chaperones [30,31,32], we
investigated whether CHIP was the ligase responsible for HIF-1a
ubiquitination in the presence of MGO. ARPE-19 cells were
transfected with c-myc CHIP and subsequently treated with the
proteasome inhibitorMG132 (orepoxomicin) inthe presenceorthe
absence of MGO. Data in Figure 6A shows that treatment with
MGO increased the association between CHIP and HIF-1a. In the
absence of MGO there was also evidence for a limited interaction
between both proteins, suggesting a potential role for CHIP in
degradation of HIF-1a under normoxia. However, under physio-
logical conditions and normoxia, the large majority of HIF-1a in
cells is presumably degraded via VHL-dependent proteolysis and
the physiological function of CHIP-mediated degradation of HIF-
1a is, at the moment, unclear.
Following treatment with MGO and proteasome inhibitors,
HIF-1a that co-immunoprecipitated with CHIP migrated at
higher molecular weights (Figure 6B), consistent with ubiquiti-
nated forms of the protein. Significantly, overexpression of CHIP
in the presence of MGO revealed an accumulation of poly-
ubiquitinated forms of HIF-1a (Figures 6C and 6D). Moreover,
CHIP mutants that either do not bind chaperones (K30A) or do
not present ubiquitin ligase activity (H260Q) decreased the
ubiquitination of HIF-1a (Figures 6C and 6D) and partially
stabilized the protein (Figure 6E), above the control levels.
Moreover, data consistently shows that CHIP K30A did not co-
immunoprecipitate with HIF-1a, while both wild type CHIP and
the mutant CHIP H260Q bound to and co-precipitated with HIF-
1a (Figure 6C). Simultaneous overexpression of the two mutants
was more effective in stabilizing HIF-1a, than individual
overexpression of each mutant (Figure 6E). Consistent with our
model, this is likely to reflect the need for both ubiquitin ligase
activity and binding of chaperones to trigger CHIP-mediated
degradation of HIF-1a in the presence of MGO. One may
speculate that the synergistic effect of the two mutants was related
to their specific mechanisms of action and competition with
endogenous CHIP. For example, in the presence of both mutants,
CHIP H260Q may block access of endogenous CHIP to its
binding site on HIF-1a, thus contributing to stabilize the
transcription factor. On the other hand, CHIP K30A may, in
addition, sequester the E2 or other cofactors required for the
activity of endogenous CHIP. In addition, overexpression of
mutant CHIP is likely to favor the formation of non-functional
CHIP dimers with endogenous CHIP [33]. This might explain the
greater stabilization of HIF-1a in the presence of both mutants.
The observation that the mutant K30A CHIP was unable to
bind and ubiquitinate HIF-1a suggests that binding to chaperones
is essential for CHIP-dependent targeting and ubiquitination of
HIF-1a. Indeed, results in Figure 6F show that treatment with
MGO increased the association between Hsp40/70 and HIF-1a.
We further observed that simultaneous overexpression of Hsp40
and Hsp70 increased the levels of CHIP associated with HIF-1a in
the presence of MGO, suggesting that CHIP/HIF-1a association
was mediated by Hsp40/Hsp70 (Figure 6G).
It should be noted that MGO-induced degradation of HIF-1a
under hypoxia appeared to be very fast (Figure 1G), which made
interaction between HIF-1a and the ancillary proteins difficult to
detect. Considering that our data clearly shows that MGO-
induced degradation of HIF-1a was independent on VHL and
Figure 5. Destabilization of HIF-1a induced by methylglyoxal was independent on VHL. (A and B) ARPE-19 cells were transiently
transfected with HIF-1a wt-V5 or HIF-1a (P402A/P564A)-V5 plasmids. Cells were subsequently subjected to hypoxia (2% O2) for 6 hours (A) or treated
with MG132 (20 mM) for 4 hours (B), in the absence or presence of MGO (3 mM for 3 hours). The cell lysates were immunoblotted against HIF-1a and
V5. (C) RCC4 VHL
-/- cells were treated with MGO (3 mM for 3 hours) and cell lysates were analyzed by western blot for HIF-1a and actin.
doi:10.1371/journal.pone.0015062.g005
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degradation of HIF-1a in the presence of MGO, we performed
a number of experiments using proteasome inhibitors, since this
increased the half-life of HIF-1a (Figure 4F), allowing the
detection of interactions between HIF-1a and binding partners,
such as CHIP, Hsp40 and Hsp70 (Figures 6A, 6B, 6F, 6G).
Loss of function studies performed in various cell types, including
ARPE-19,RCC4 VHL
2/2 andCos-7cells,bysilencing CHIP with
shRNAs (Figure 7A and 7B), clearly showed that MGO-dependent
degradation of HIF-1a is a general mechanism not restricted to one
cell type and that is likely to have important biological functions.
Indeed, depletion of CHIP by shRNAs decreased the accumulation
Figure 6. CHIP polyubiquitinated HIF-1a in the presence of methylglyoxal. (A and B) ARPE-19 cells were transiently transfected with the
CHIP wt c-myc plasmid and treated with MG132 (20 mM) for 4 hours in the absence or presence of MGO (3 mM for 40 or 70 minutes). HIF-1a (A) or c-
myc (B) were immunoprecipitated and the immunoprecipitates were probed for c-myc and HIF-1a. (C) ARPE-19 cells were transfected with CHIP wt c-
myc or with the dominant negatives CHIP K30A c-myc and CHIP H260Q c-myc, simultaneously or separately, and treated with MG132 (20 mM) for
41 hours in the presence or absence of MGO (3 mM for 70 minutes). HIF-1a was then immunoprecipitated and the immunoprecipitates were blotted
against HIF-1a, c-myc and ubiquitin (P4D1). (D) ARPE-19 cells were transfected with CHIP wt c-myc or with the dominant negative mutants CHIP K30A
c-myc and CHIP H260Q c-myc, simultaneously or separately, and subjected to hypoxia for 6 hours in the presence or absence of MGO (3 mM for 70
minutes). HIF-1a was then immunoprecipitated and the immunoprecipitates were blotted for HIF-1a and ubiquitin (P4D1). (E) ARPE-19 cells were
transfected with CHIP wt c-myc, CHIP K30A c-myc or/and CHIP H260Q c-myc dominant negatives, either simultaneously or separately, and subjected
to hypoxia for 6 hours in the presence or absence of MGO (3 mM for 70 minutes). Proteins were separated by SDS-PAGE, transferred to PVDF
membranes and probed for HIF-1a and actin. (F) ARPE-19 cells were treated with MG132 (20 mM for 4 hours) either in the presence or absence of
MGO (3 mM for 40 or 70 minutes). HIF-1a was immunoprecipitated and the immunoprecipitates were probed using antibodies against HIF-1a, Hsp70
and Hsp40. (G) ARPE-19 cells were transfected simultaneously with CHIP-c-myc and V5-tagged Hsp40 and/or HA-tagged Hsp70. Cells were
subsequently treated with MG132 (20 mM) for 4 hours and MGO (3 mM) for the last 70 minutes of incubation. HIF-1a was immunoprecipitated and
the immunoprecipitates were blotted against HA, V5 and c-myc. IP controls were carried out both with no antibody and with an irrelevant mouse
IgG1 antibody (for example anti-GFP). The word ‘‘Mock’’ in the figures refers to a control with an empty vector.
doi:10.1371/journal.pone.0015062.g006
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antibodies (Figure 7D), decreased ubiquitination of HIF-1a and led
to the stabilization of the protein under hypoxia in the presence of
MGO in ARPE-19 (Figures 7C), RCC4 VHL
2/2 (Figures 7D) and
Cos-7 cells (Figure 7E). Significantly, silencing of CHIP prevented
degradation of HIF-1a under high glucose and hypoxia (Figure 7F),
emphasizing the putative relevance of CHIP-mediated degradation
of HIF-1a in pathophysiological conditions such as diabetes.
Discussion
In this study we elucidated a new pathway for degradation of
HIF-1a. Data presented in this paper is consistent with a
molecular mechanism in which HIF-1a-modification by MGO
leads to increased association with the molecular chaperones
Hsp40/70. This, in turn, recruits CHIP, leading to the
ubiquitination and proteasome-dependent degradation of HIF-
1a (Figure 8). We further showed that this mechanism is
independent on the recruitment of pVHL and does not require
hydroxylation of HIF-1a. This new mechanism is triggered by
accumulation of MGO and is likely to have a significant
physiological impact in conditions with increased availability of
glucose, such as diabetes. Indeed, we showed that exposure of cells
to high glucose leads to a sustained increase in the intracellular
levels of MGO, which were sufficient to activate the degradation
of HIF-1a. Moreover, scavenging of intracellular MGO by
Figure 7. Silencing of CHIP stabilized HIF-1a protein in the presence of methylglyoxal in ARPE-19, Cos-7 and RCC4 cells. (A) ARPE-19
cells were infected with pAd shRNA-hCHIP for 48 hours. Cells were subsequently lysed and protein extracts were immunoblotted against
endogenous CHIP and actin. (B) ARPE-19 cells were co-infected with pAd V5-hCHIP and pAd shRNA-hCHIP for 24 hours. The cell lysates were analyzed
by western blotting using anti-V5 and anti-actin monoclonal antibodies. (C) ARPE-19 cells were infected with pAd shRNA-hCHIP for 48 hours and
during the last 6 hours of incubation, cells were subjected to hypoxia in the presence of MGO (3 mM for the last 70 minutes). Cell lysates were used
to immunoprecipitate HIF-1a and the immunoprecipitates were probed with antibodies against HIF-1a and ubiquitin (P4D1). The data in the graph
represents the mean 6 SD of at least three independent experiments. ** p,0.01, significantly different from control (one-way ANOVA with the
Dunnet’s comparison test). (D) RCC4 VHL
-/- cells, infected with pAd shRNA-hCHIP for 48 hours, were treated with MGO (3 mM for 70 minutes). Cell
lysates were used to immunoprecipitate HIF-1a and the immunoprecipitates were blotted against HIF-1a and ubiquitin (P4D1). (E) Cos-7 cells were
infected with pAd shRNA-hCHIP for 48 hours and, during the last 6 hours of incubation, cells were subjected to hypoxia and treated with MGO (3 mM
for the last 70 minutes). Cell lysates were used to immunoprecipitate HIF-1a and the immunoprecipitates were probed for HIF-1a and ubiquitin
(P4D1). IP controls were carried out both with no antibody and with an irrelevant mouse IgG1 antibody (for example anti-GFP). (F) ARPE-19 cells were
grown in 15 mM (basal DMEM: F12 medium) or 40 mM of D-glucose during 10 days. After 8 days of incubation, cells were infected with pAd shRNA-
hCHIP for 48 hours. During the last 6 hours of incubation, cells were subjected to hypoxia and subsequently lysed. Proteins were blotted against HIF-
1a and actin. The word ‘‘Mock’’ in the figures refers to a control with a scrambled shRNA sequence.
doi:10.1371/journal.pone.0015062.g007
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under high glucose. Additionally, MGO-induced degradation of
HIF-1a led to decreased transcriptional activity of HIF-1 and
decreased expression of VEGF under hypoxia. Significantly, we
also observed that data obtained in cell culture systems is
consistent with observations in retinas of diabetic animals. Indeed,
increased availability of MGO in the retina of Goto-Kakizaki rats
was accompanied by decreased levels of HIF-1a and VEGF, as
well as increased levels of apoptotic markers and enhanced
vascular permeability [34]. The reduction of VEGF expression
under high glucose and in response to hypoxia was also described
before [22,35]. The authors suggested that increased levels of
MGO under hyperglycemia induce HIF-1a [22] and p300
modifications [35], which were sufficient to disrupt the interaction
between HIF-1a/HIF-1b and HIF-1a/p300, leading to loss of
HIF-1 transcriptional activity and poor response to hypoxia.
Although this and other modifications induced by MGO cannot
be excluded and are likely to account for the plethora of noxious
effects of MGO in cells, our study provides robust data that
elucidates an independent molecular mechanism whereby MGO
can lead to proteasomal degradation of HIF-1a mediated by
CHIP. It is perhaps interesting to note that the two observations
are not inconsistent. Indeed, it is plausible that the decreased
interaction between HIF-1a/p300 and HIF-1a/HIF-1b in the
presence of MGO increases the amount of modified and
monomeric HIF-1a that is available to undergo degradation
through a CHIP-mediated pathway.
In the canonical mechanism for activation of HIF-1, HIF-1a is
believed to be inherently stable under hypoxia and pVHL is
thought to be virtually the single ubiquitin ligase targeting HIF-1a
for proteasomal degradation under normoxia. Over the last five
years, a number of reports suggested that HIF-1a might be
destabilized under hypoxia and that interaction of HIF-1a with
ancillary proteins might promote its degradation. In many
instances the mechanism and molecular events that underlie
HIF-1a targeting for pVHL/oxygen-independent degradation are
not well understood. Nevertheless, a few proteins were shown to
interact with HIF-1a promoting its proteasome-dependent
degradation and some proteins were identified as putative ligases
or components of ubiquitin ligase complexes that are able to
ubiquitinate HIF-1a, promoting its proteasomal degradation.
These include SMURF2, p53/Mdm2 complex, RACK1 and
HAF [36,37,38,39,40]. Of significance for the results discussed
here is a report that p53 is not involved in destabilization of HIF-
1a in high glucose, since destabilization of HIF-1a is still observed
in cells deficient in p53 when exposed to high glucose [7]. More
recently, it was also shown that HIF-1a can be destabilized by a
mechanism that is independent on both pVHL and p53 [41]. This
pathway is activated in response to histone deacetylase inhibitors
(HDACIs) and appears to involve destabilization of the Hsp70/90
chaperone axis resulting in proteasomal degradation of HIF-1a
[41].
To the best of our knowledge, there are very few studies
unequivocally elucidating ubiquitin ligases that target HIF-1a for
degradation in a VHL-independent manner. In this paper, we do
elucidate an entirely novel mechanism for ubiquitination and
degradation of HIF-1a in a VHL-independent manner. Signifi-
cantly, this alternative pathway is activated in response to
intracellular accumulation of MGO and involves recruitment of
Hsp40/70 and ubiquitination of the transcription factor by the E3
ligase CHIP. However, we do not exclude the possibility that this
pathway might be activated by other forms of stress nor do we
exclude a function for CHIP-dependent degradation of HIF-1a
under physiological or pathophysiological conditions. Indeed,
while the present work was in progress, it was reported that Hsp70
and CHIP can mediate ubiquitination and degradation of HIF-1a
under prolonged hypoxia, consistent with the observation that
prolonged hypoxia led to a decrease in HIF-1a protein levels [42].
CHIP has a critical role in protein quality control by
ubiquitinating misfolded or otherwise damaged proteins through
interaction with molecular chaperones [43,44]. The observation
that CHIP is also able to ubiquitinate HIF-1a reveals a new
function for CHIP and an unanticipated association between high
glucose, the ubiquitin-proteasome pathway and cell response to
hypoxia.
It is conceivable that the mechanism reported in this manuscript
is involved in MGO-induced downregulation of other cellular
proteins. However, based on the present data and on the current
state of art it seems prudent neither to over-generalize the
mechanism nor to restrict it to HIF-1a. For example, MGO was
shown to downregulate the phosphorylation of STAT3 and
decrease its transcription activity [45]. Moreover, MGO was also
Figure 8. Proposed model for MGO-dependent degradation of HIF-1a. MGO induces modifications on HIF-1a protein (as for example,
formation of MG-H1 adducts) and promotes increased association of Hsp40/70 to HIF-1a. This association leads to recruitment of CHIP, which
promotes polyubiquitination and proteasomal degradation of HIF-1a. MGO-induced degradation of HIF-1a is activated under high glucose and is
inhibited by overexpression of glyoxalase I.
doi:10.1371/journal.pone.0015062.g008
MGO Induces HIF-1a Ubiquitination by CHIP
PLoS ONE | www.plosone.org 9 November 2010 | Volume 5 | Issue 11 | e15062shown to modify the co-repressor mSin3A, which results in
increased recruitment of O-GlcNAc-transferase, with consequent
increased modification of the transcription factor Sp3 by O-linked
N-acetylglucosamine [46]. MGO is also known to suppress TNF-
a-induced NF-kB activation by inhibiting NF-kB/DNA binding
[47]. To the best of our knowledge, the effect of MGO on these
and other transcription factors did not result in increased protein
degradation. Consistently, we showed in this study that the
transcription factor Nrf-2 is not downregulated by MGO.
However, it is still possible that some transcription factors or
other proteins may be downregulated in response to MGO.
Indeed, there are a few examples where treatment with MGO was
shown to lead to proteasome-dependent degradation of specific
substrates. For example, it was shown that Raf-1 protein-serine/
threonine kinase is degraded by an ubiquitin-proteasome-depen-
dent mechanism in response to MGO [15]. Moreover, CML-
modified proteins in glyoxal-treated cells were shown to be
substrates for ubiquitin conjugation, suggesting a potential
mechanism by which these modified proteins may be marked for
degradation [48]. These observations raise the possibility that the
ubiquitin-proteasome pathway might be implicated in degradation
of proteins modified by MGO and presumably by other glycation
products, which typically accumulate in diabetes.
The results reported in this paper are consistent with a number
of sparse results and provide a rationale for observations such as
that hyperglycemia inhibits hypoxia-induced stabilization of HIF-
1a. Moreover, we have identified CHIP as the ubiquitin ligase that
promotes proteasomal degradation of HIF-1a in the presence of
MGO. Significantly, loss of function studies, using shRNAs against
CHIP, clearly showed that endogenous CHIP is required to target
HIF-1a for proteasomal degradation in the presence of physio-
logically relevant levels of MGO. This observation highlights the
importance of this pathway under physiological conditions, as well
as in pathologies associated with high glucose and/or disruption of
cell response to hypoxia, including diabetes.
Although we did not address directly the modifications induced
by MGO on HIF-1a that recruit Hsp40/70, we suggest that
MGO-induced modification of HIF-1a (for example, by forming
MG-H1 adducts) possibly leads to unfolding and exposure of
hydrophobic residues at the surface of the protein. These
hydrophobic patches are, most likely, recognized by the molecular
chaperones Hsp40/70, which subsequently recruit CHIP to
induce ubiquitination of HIF-1a and its subsequent degradation.
The identification of the modified residues, as well as the type of
MGO-induced modifications (i.e. by mass spectrometry), are
interesting issues to pursue in the future and will certainly provide
additional clues on the mechanism underlying the binding of
Hsp40/70 to HIF-1a.
Materials and Methods
Cells Culture and Treatments
The ARPE-19 cells (LGC Promochem, Teddington, UK) were
cultured in Dulbecco’s modified Eagle’s medium/Ham’s F12
(DMEM:F12; 1:1) supplemented with 10% fetal bovine serum
(FBS), antibiotics (100 U/ml penicillin, 100 mg/ml streptomycin
and 250 ng/ml amphotericin B) and GlutaMax (1x). The renal
carcinoma cell line RCC4 VHL
-/- was grown in RPMI 1640
medium supplemented with 10% FBS, antibiotics and glutamine
and was kindly provided by Dr. C. Buys (University Medical
Center of Groningen, Netherlands). The Cos-7 cells (LGC
Promochem, Teddington, UK) were cultured in DMEM supple-
mented with 10% FBS, antibiotics and glutamine. All media,
GlutaMax and non-essential amino acids were purchased from
Invitrogen (Carlsbad, CA, USA). When appropriate, cells were
treated with the following agents: 250 mM cobalt chloride (CoCl2,
Sigma-Aldrich), 100 mM - 3 mM methylglyoxal (MGO, Sigma-
Aldrich, St. Louis, MO, USA), 10 mM epoxomicin (Boston
Biochem, Cambridge, MA, USA), 20 mM MG132 or Z-LLL-
CHO (Calbiochem, San Diego, CA, USA) and 10 mM MG262 or
Z-Leu-Leu-Leu-B(OH)2 (Boston Biochem, Cambridge, MA,
USA). Hypoxic treatments (5%CO2, 2%O2, 93% N2,3 7 uC) were
done in a Nuaire N4950E incubator with gas control (Nuaire,
Plymouth, MN, USA).
Western Blot Analysis
After treatment, cells were washed twice in phosphate-buffered
saline (PBS) solution, denatured with 2x Laemmli buffer, boiled at
100uC and sonicated. Whole cell extracts were resolved by SDS-
PAGE and electrophoretically transferred onto polyvinylidene
fluoride (PVDF) membranes (GE Healthcare Bio-Sciences,
Uppsala, Sweden). The membranes were blocked with 5% nonfat
milk in TBS-T and probed for various proteins. Immunoreactive
bands were visualized with ECL (GE Healthcare Bio-Sciences,
Uppsala, Sweden). The following antibodies were used: mouse
anti-HIF-1a clone H1alpha67 1:500 (Abcam, Cambridge, UK),
mouse anti-actin clone C4 1:1,000 (Millipore-Chemicon, Billerica,
MA, USA), mouse anti-V5 tag clone 2F11F7 1:2,000 (Invitrogen,
Carlsbad, CA, USA), mouse anti-ubiquitin clone P4D1 1:1,000
(Covance, Princeton, NJ, USA), mouse anti-ubiquitin clone FK1
1:1000 (Biomol-Enzo Life Sciences, Farmingdale, NY, USA),
mouse anti-c-myc clone 9E10 1:500 (Zymed-Invitrogen, Carlsbad,
CA, USA), mouse anti-Hsp70 clone C92F3A-5 1:300 (Stressgen-
Enzo Life Sciences, Farmingdale, NY, USA), mouse anti-CML
clone CMS-10 1:500 (TransGenic INC., Kumamoto, Japan),
mouse anti-MG-H1 1:500 (originally provided by Dr. M.
Brownlee from the Albert Einstein College of Medicine, New
York, NY, USA) [46], rabbit anti-HA 1:200 (Zymed-Invitrogen,
Carlsbad, CA, USA), rabbit anti-Hsp40 1:2,000 (Stressgen-Enzo
Life Sciences, Farmingdale, NY, USA), goat anti-STUB1 1:500
(Abcam, Cambridge, UK) and horseradish peroxidase-conjugated
secondary goat anti-mouse, goat anti-rabbit and rabbit anti-goat
1:7,500 (Bio-Rad, Hercules, CA, USA).
Determination of Intracellular Concentration of
Methylglyoxal by HPLC
After the treatments, ARPE-19 cells (7610
5) cultured in
60615 mm plates were washed twice with ice-cold PBS, scraped
in 100 ml 0.1 M acetic acid and homogenized by sonication. The
intracellular concentration of MGO was determined according to
previously reported method [49]. Briefly, 50 ml of sample was
mixed with 200 ml of 0.1 M potassium phosphate buffer pH 7.0,
200 ml of ethanol and 50 ml of freshly prepared derivatization
20 mM 1,2-diamino-4,5-dimethoxybenzene reagent (DDB; Invi-
trogen, Carlsbad, CA, USA) dissolved in 10 mM HCl. The
mixture was incubated at least four hours at room temperature
and then centrifuged for 10 minutes at 16,000 g. Subsequently,
MGO was determined by reverse-phase HPLC. The HPLC
system consisted of a L-6200A Intelligent Pump, a F-1080
Fluorescence Detector (Hitachi, Tokyo, Japan) and a Waters
mBondapak
TM C18 column (10 mm, 3.96300 mm) (Waters,
Milford, MA, USA). Mobile phase A was a mixture of 10 mM
potassium phosphate buffer (pH 3.0) and acetonitrile (90/10, v/v).
Mobile phase B consisted of a mixture of acetonitrile and water
(70/30, v/v). Samples (20 ml) were injected and separation was
performed with a linear gradient from 0-100% mobile phase B
over 28 minutes. The flow rate was set at 1.0 ml/min and
fluorescence detection was performed with excitation and emission
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determined by integration of peak areas using appropriate external
standards.
Metabolic labeling
ARPE-19 cells cultured in 60615 mm plates were incubated in
methionine- and cysteine-free DMEM for 40 minutes and
subsequently washed twice with ice-cold PBS. L-[
35S] methio-
nine/cysteine (PerkinElmer, Waltham, MA, USA) was then added
to a final concentration of 100 mCi/ml and cells were incubated
for 4 hours under hypoxia. After metabolic labeling, the
radioactive medium was removed and cells were washed twice
with PBS. Cells were then recultured in complete medium
containing ten fold excess of methionine/cysteine and treated as
mentioned in legend of each figure. Cells were harvested at
different time points in 100 ml of 0.5% NP-40 lysis buffer [50 mM
Tris-HCL pH 7.4, 1501 mM NaCl, 10 mM IOD, 2 mM PMSF,
20 mM Na3MoO4 and protease inhibitor cocktail (Roche Applied
Science, Indianapolis, IN, USA)]. Samples were pre-cleared with
25 ml of Protein G Sepharose (GE Healthcare Bio-Sciences,
Uppsala, Sweden) for 30 minutes and then HIF-1a was
immunoprecipitated as described below. Proteins were resolved
by SDS-PAGE, the gels were dried and radiolabeled HIF-a
protein was assessed by autoradiography.
Immunoprecipitation
Cells cultured in 60615 mm plates were washed twice with
PBS, scraped off the dishes and collected in ice-cold PBS. Pellets
were resuspended in 100 ml of lysis buffer (50 mM Tris-HCl
pH 7.4, 150 mM NaCl, 10 mM IOD, 2 mM PMSF, 20 mM
Na3MoO4, 0.5% NP-40 and protease inhibitor cocktail) and
incubated for 30 minutes on ice. Following centrifugation at
16,000 g for 10 minutes supernatants were transferred to new
tubes and 2.5 mg of anti-HIF-1a or anti-c-myc were added. The
reaction was incubated overnight at 4uC with gentle agitation.
Thereafter, 50 ml of protein G–Sepharose (GE Healthcare Bio-
Sciences, Uppsala, Sweden) were added and incubations proceed-
ed at 4uC for 2 hours. Beads were washed 3 times with lysis buffer
and the immunoprecipitated proteins were denatured with 2x
Laemmli buffer and boiled at 100uC. Samples were loaded on
SDS-PAGE and western blot analyses were performed. IP controls
were carried out both with no antibody and with an irrelevant
mouse IgG1 antibody (for example anti-GFP).
Immunocytochemistry
Cells were grown on coverslips and subjected to the relevant
treatments. Cells were subsequently washed twice in PBS and fixed
with 4% paraformaldehyde (PFA) for 10 minutes. The fixed cells
were permeabilized with 1% Triton X-100 (v/v) for 10 minutes
and blocked with goat serum (1:10) for 20 minutes prior to
incubation with primary antibodies for 1 hour at room temper-
ature. The cells were then rinsed three times with 0.02% BSA in
PBS and incubated with DAPI 1:5,000 and FITC/Texas Red-
conjugated goat anti-mouse or anti-rabbit 1:100 (Invitrogen,
Carlsbad, CA, USA) for 1 hour at room temperature. The
coverslips were washed with 0.02% BSA and mounted with
Glycergel (Dako, Glostrup, Denmark). The cells were imaged by
confocal microscopy using the MRC600 image system (Bio-Rad,
Hercules, CA, USA).
Measurement of 20S proteasome activity
Cells were washed twice with PBS, lysed with a Tris buffer
(50 mM Tris pH 7.4, 1 mM DTT) and sonicated. After
centrifugation (16,000 g for 10 minutes at 4uC), protein concen-
tration was determined using the Coomassie method and 40 mgo f
protein was incubated with the following fluorogenic substrates:
100 mM Suc-LLVY-MCA for the chymotrypsin-like activity
(Biomol-Enzo Life Sciences, Farmingdale, NY, USA); 25 mM
Boc-LRR-MCA for the trypsin-like activity (Biomol-Enzo Life
Sciences, Farmingdale, NY, USA); 150 mM Z-LLE-MCA for the
caspase-like activity (Calbiochem, San Diego, CA, USA). The
proteasome activities were monitored during 1 hour at 37uC, for
periods of 5 minutes (excitation wavelength at 380 nm; emission
wavelength at 460 nm). Absorbance was measured on a Biotek
Synergy HT spectrophotometer (Biotek, Winooski, VT, USA),
using the Gen 5 software to monitor the results (Biotek, Winooski,
VT, USA).
Plasmids
Human CHIP (GeneBank accession number NM_005861) was
amplified by PCR from a human leukocyte cDNA library, while
human glyoxalase I (GeneBank accession number NM_006708)
was PCR-amplified from the pCMS-EGFP hGLOI vector [21].
Both amplifications were performed using flanking primers
containing EcoRI and SalI restriction sites and the sequences were
cloned into pENTRV5-C2 [50,51] to generate pENTR/V5-
hCHIP and pENTR/V5-hGLOI. In order to produce hCHIP
and hGLOI adenovirus, these vectors were recombined with the
pAd/BLOCKiT-DEST adenoviral vector from Invitrogen using
Gateway technology according to manufacturers’ instructions. For
this work we also used the following plasmids: pcDNA3.1 c-myc-
CHIP wt, pcDNA3.1 c-myc-CHIP K30A, pcDNA3.1 c-myc-
CHIP H260Q [52]; pcDNA6 Hdj1/Hsp40 wt-V5 [53]; pcDNA3
Hsp70 wt-HA [54]; pcDNA3 HIF-1a wt-V5 and pcDNA3 HIF-1a
(P402A and P564A)-V5 [55]; pcDNA3 HA-hHIF1a wt [2].
Adenoviral CHIP shRNA production and infection
For shRNA targeting of human CHIP, the oligonucleotides
were annealed and ligated into pENTR/U6 according to
manufacturers’ instructions. The following oligonucleotides were
used: shRNA1 forward 59-CACCGGAGATGGAGAGCTAT-
GATGACGAATCATCATAGCTCTCCATCTCC-39; shRNA1
reverse 59- AAAAGGAGATGGAGAGCTATGATGATTCGT-
CATCATAGCTCTCCATCTCC-39; shRNA2 forward 59-CAC-
CGGCTATGAAGGAGGTTATTGACGAATCAATAACCTC-
CTTCATAGCC-39; shRNA2 reverse 59-AAAAGGCTATGAA-
GGAGGTTATTGATTCGTCAATAACCTCCTTCATAGCC-
39 (shRNA target sequence is underlined). All plasmids were
verified by DNA sequencing. Site-specific recombination between
pENTR286 attL sites and pAd/BLOCKiT-DEST attR sites was
performed using LR clonase II (Invitrogen, Carlsbad, CA, USA),
according to the manufacturer’s instructions. Pac1-digested
recombinant packaging vector was then transfected into a
producer cell line HEK293A and recombinant viral particles
were harvested after lysis of infected cells 8-10 days later [50]. The
word ‘‘Mock’’ in the gene silencing figures refers to a control with
a scrambled shRNA sequence.
Transient Transfection
One day before transfection, cells were seeded in 60615 mm
plates in 2.5 ml of medium so that the cells were 90% confluent at
the time of transfection. 4 mg of plasmid DNA were used per dish
and transfections were carried out using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s
specifications. After transfection, cells were incubated at 37uCi na
CO2 incubator for 24-30 hours prior to test for transgene
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with an empty vector.
Reporter-gene Assay
ARPE-19 cells were plated in 60615 mm dishes at subconfluent
density and transfected with pT81 HRE-luciferase [7], using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The
plasmid pT81/HRE-luciferase contains three tandem copies of
the erythropoietin hypoxia response element (HRE) in front of the
herpes simplex thymidine kinase promoter. Twenty-four hours
after transfection, cells were treated as mentioned and then
assayed for luciferase activity, which was measured using a LMax
II 384 ROM v1.04 reader and SoftMax Pro 5 software (Molecular
Devices, Sunnyvale, CA, USA), as described by the manufactur-
er’s specifications. The different treatments to which cells were
subjected had no effect on the readout of the luciferase reporter
assay (assessed by transfection of pCMV luciferase).
Determination of VEGF in supernatants
The concentration of diffusible VEGF-A121, 165 in the cell
culture supernatants was measured by a Quantikine VEGF
enzyme-linked immunosorbent assay kit (R&D Systems, Minnea-
polis, MN, USA), using monoclonal antibodies directed against
human VEGF. Absorbance was measured at 450 nm, with
wavelength correction at 570 nm, on a Biotek Synergy HT
spectrophotometer (Biotek, Winooski, VT, USA), using the Gen 5
software to monitor the results (Biotek, Winooski, VT, USA).
Quantitative Real-Time PCR
Following the relevant treatments, total RNA was purified
according to the manufacturer’s specifications of Qiagen RNeasy
mini kit (Qiagen, Valencia, CA, USA) and treated with RNase-
free DNase I (GE Healthcare Bio-Sciences, Uppsala, Sweden).
SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA,
USA) and random hexadeoxynucleotide primers were used to
synthesize cDNA. For human VEGF mRNA quantification, it was
used the SYBR Green PCR master mix (Bio-Rad, Hercules, CA,
USA), according to the manufacturer’s instructions, and the cDNA
amplification was performed using the following set of primers:
hVEGF forward 59-CAGAATCATCACGAAGTG-39; hVEGF
reverse 59-TCTGCATGGTGATGTTGGAC-39; 18S rRNA for-
ward 59-GTCTGCCCTATCAACTTTC-39; 18S rRNA reverse
59-TTCCTTGGATGTGGTAGC-39. The realtime PCR analyses
were conducted on a ABI Prism 7000 quantitative PCR system
(Applied Biosystems, Foster City, CA, USA).
Statistical Analysis
Data are reported as the means 6 standard deviation of at least
three independent experiments. Comparisons between multiple
groups were performed by one-way analysis of variance test
(ANOVA) with Dunnet’s or Tukey’s multiple comparison tests,
using GraphPad Prism 5.0 software (GraphPad Software, La Jolla,
CA, USA). For comparison between two groups, the paired t test
was used. In all cases, p,0.05 was considered significant.
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